Clinical Trial Update: Alectinib Pharmacokinetic in Patients With NSCLC [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a pharmacokinetic study of alectinib in patients with non-small cell lung cancer (ALK mutation), spanning Phase 1 and Phase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alectinib (alectinib)

Snippet

Sponsor: Instituto Nacional de Cancerologia de Mexico | Conditions: Non-small Cell Lung Cancer Stage IIIB, ALK Gene Mutation | Phase 1, Phase 2 | Status: RECRUITING